CurrentBlue KCPolicy POL-PP-313

Testing for Vector-borne Infections

Laboratory test coverage and reimbursement guidance for diagnostic testing of arthropod-borne (vector-borne) infections for Blue KC members; applies to professional and facility providers, and laboratories.

Policy Summary

PayerBlue KC

PolicyTesting for Vector-borne Infections

Policy CodePolicy POL-PP-313

Change TypeNo material changes

Effective DateJul 1, 2025

Next Review DateJul 1, 202619d

Key ActionVerify member benefits and coverage prior to ordering testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

MultiplePathogen groups

ListedEnumerated codes

Repeat up to 3xMalaria repeat

Up to 12wZika NAAT window

Coverage Criteria

Covered testing by suspected infection

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Babesiosis: For individuals suspected of babesiosis: Giemsa- or Wright-stain of a blood smear, nucleic acid amplification testing (NAAT), or IgG or IgM indirect immunofluorescence antibody (IFA) assay for Babesia (initial and confirmatory testing should occur a minimum of 2 weeks apart).

Relapsing fever (Borrelia spp.): For suspected relapsing fever: HTRF — serologic assays for Borrelia antibodies or NAAT for Borrelia miyamotoi; LBRF — peripheral blood smear microscopy or NAAT for Borrelia recurrentis; STRF/TBRF — dark-field microscopy, Wright- or Giemsa-stained blood smear, NAAT for Borrelia spp., or serologic assays.

Chikungunya: Viral culture, NAAT of blood, or IFA assay for IgM antibodies during acute and convalescent phases may be reimbursed for individuals suspected of chikungunya.

Colorado tick fever (CTF): For suspected CTF: NAAT testing or IFA for CTF-specific IgM antibodies may be reimbursed.

Dengue virus (DENV): For suspected dengue: NAAT, IgM MAC-ELISA, NS1 ELISA, and confirmatory plaque reduction neutralization testing may be reimbursed; IgG ELISA or hemagglutination testing for DENV may not be reimbursed.

Ehrlichiosis / Anaplasmosis: For suspected ehrlichiosis or anaplasmosis: NAAT of whole blood, IFA IgG, or microscopy for morulae detection may be reimbursed; IFA IgM assays and standard blood culture are not reimbursed.

Malaria: For suspected malaria: rapid immunochromatographic diagnostic test or smear microscopy to diagnose malaria, determine Plasmodium species, lifecycle stage, and quantify parasitemia may be reimbursed (smear may be repeated up to 3 times within 3 days if initial microscopy is negative); NAAT may be reimbursed to confirm Plasmodium species.

repeat up to 3 times within 3 days if initial microscopy is negative

Rickettsial disease: For suspected rickettsial disease: IFA IgG assay may be reimbursed (initial and confirmatory testing should occur a minimum of two weeks apart); standard blood culture, NAAT, and IFA IgM are not reimbursed.

West Nile virus (WNV): For suspected WNV: IFA for WNV-specific IgG or IgM in serum or CSF and confirmatory plaque reduction neutralization testing may be reimbursed; nucleic acid detection may be reimbursed for immunocompromised individuals but NAAT is not reimbursed for immunocompetent individuals.

Yellow fever virus (YFV): For suspected YFV: NAAT or serologic assays for virus-specific IgM/IgG and confirmatory plaque reduction neutralization testing may be reimbursed.

Zika virus: For suspected Zika: NAAT may be reimbursed up to 12 weeks after symptom onset for symptomatic pregnant individuals with relevant travel/exposure or sexual contact with exposed persons; NAAT reimbursed for symptomatic non-pregnant travelers within 7 days of symptom onset; broader Zika NAAT and IgM with confirmatory plaque reduction neutralization testing may be reimbursed for specified pregnancy/fetal/infant scenarios and symptomatic individuals with travel/exposure history. NAAT/IgM testing for symptomatic non-traveling non-pregnant individuals and testing of asymptomatic individuals generally may not be reimbursed per policy conditions.

Culture testing for relapsing fever caused by Borrelia spp. is explicitly listed as not reimbursed and should be avoided when ordering for suspected relapsing fever (see testing alternatives in policy). The policy also states that the use of an IFA for Plasmodium (malaria) antibodies is not reimbursed, so serologic IFA for malaria should not be used for diagnostic confirmation. In addition, IFA IgM assays are not reimbursed for certain conditions (for example, ehrlichiosis/anaplasmosis and rickettsial disease) and standard blood culture is similarly excluded for some of these diagnoses; order only those assays and methods the policy identifies as covered for the specific suspected infection.

When clinical suspicion supports testing, a range of pathogen-specific diagnostics may be reimbursed: for babesiosis, Giemsa- or Wright-stained blood smear, NAAT, or IgG/IgM IFA with initial and confirmatory serology separated by at least two weeks; for chikungunya, viral culture, NAAT of blood, or IFA IgM during acute and convalescent phases; for Colorado tick fever (CTF), NAAT or IFA for CTF-specific IgM; for dengue (DENV), NAAT, IgM MAC-ELISA, NS1 antigen ELISA and confirmatory plaque reduction neutralization testing (note that dengue IgG ELISA or hemagglutination testing may not be reimbursed); for ehrlichiosis/anaplasmosis, NAAT of whole blood, IFA IgG, or microscopy for morulae (IFA IgM and standard blood culture are not reimbursed); for malaria, rapid immunochromatographic tests or smear microscopy to diagnose and speciate (smear may be repeated up to 3 times within 3 days if initial microscopy is negative) with NAAT available to confirm Plasmodium species; for rickettsial disease, IFA IgG with acute and convalescent testing at least two weeks apart (standard blood culture, NAAT, and IFA IgM may not be reimbursed in many instances); for West Nile virus, IFA IgG/IgM in serum or CSF and confirmatory neutralization testing may be reimbursed, with NAAT reimbursed only for immunocompromised individuals; for yellow fever virus, NAAT or serology with confirmatory neutralization testing may be reimbursed; and for Zika virus, NAAT and IgM with confirmatory neutralization testing are reimbursed in specified pregnancy/fetal/infant scenarios and time windows (including NAAT up to 12 weeks post-onset for symptomatic pregnant individuals and within 7 days for symptomatic non-pregnant travelers).

Covered Indications for Testing

Clinical suspicion of specific vector-borne infections

Clinical suspicion of specific vector-borne infections based on signs/symptoms and exposure or travel history:

Clinical suspicion — top-level: Testing is covered when there is clinical suspicion of one of the following vector-borne infections based on compatible signs/symptoms and relevant exposure or travel history: babesiosis; relapsing fever (Borrelia spp. — HTRF, LBRF, STRF/TBRF); chikungunya; Colorado tick fever (CTF); dengue virus (DENV); ehrlichiosis and/or anaplasmosis; malaria; rickettsial diseases; West Nile virus (WNV); yellow fever virus (YFV); and Zika virus.

Coding and Procedure Codes

Enumerated CPT codesCPT

86280	Hemagglutination inhibition test (HAI)
86382	Neutralization test, viral
86619	Antibody; Borrelia (relapsing fever)
86666	Antibody; Ehrlichia
86750	Antibody; Plasmodium (malaria)
86753	Antibody: protozoa, not elsewhere specified
86757	Antibody; Rickettsia
86788	Antibody; West Nile virus, IgM
86789	Antibody; West Nile virus
86790	Antibody: virus, not elsewhere specified

1–10 of 18

1/2

Additional molecular and proprietary test codesmixed

87478	Infectious agent detection by nucleic acid (DNA or RNA); Borrelia miyamotoi, amplified probe technique
87484	Infectious agent detection by nucleic acid (DNA or RNA); Ehrlichia chaffeensis, amplified probe technique
87662	Infectious agent detection by nucleic acid (DNA or RNA); Zika virus, amplified probe technique
87798	Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism
87899	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; not otherwise specified
0043U	Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgM (IGeneX)
0044U	Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgG (IGeneX)

inv-07: Malaria repeat microscopy — guidance

FrequencyRepeat microscopy up to 3 times within a 3-day period if initial smear is negative

IndicationSuspected malaria when initial microscopy is negative but clinical suspicion persists (e.g., fever, recent travel to endemic area)

Permitted methodsGiemsa- or Wright-stained blood smear (thin and/or thick) or rapid immunochromatographic diagnostic test used initially; NAAT may be used to confirm species

ConfirmationNAAT testing may be reimbursed to confirm Plasmodium species after microscopy/rapid test diagnosis

Provider Actions and Operational Notes

Prior Authorization

Verify member benefits

Verify member benefits before ordering testing. Coverage for vector-borne infection testing is benefit-dependent and may vary by plan; confirm individual benefit coverage, prior authorization requirements, and applicable limits at the time of the request.

Confirm eligibility and coverage for the requested tests prior to specimen collection or ordering
Check for prior authorization requirements and any test-specific limits or documentation needs

Note

Malaria diagnostic approach

For suspected malaria, initial diagnosis should be performed with smear microscopy or a rapid immunochromatographic diagnostic test to detect infection, determine Plasmodium species, stage, and quantify parasitemia. Microscopy may be repeated up to three times within three days if initial microscopy is negative but clinical suspicion remains high. NAAT may be used to confirm Plasmodium species when needed.

Initial testing: smear microscopy or rapid diagnostic test (RDT)
Repeat microscopy: up to three times within three days if initial smear is negative and suspicion persists
Species confirmation: NAAT may be reimbursed to confirm Plasmodium species

Documentation Required

Babesia serology timing

For suspected babesiosis, serologic testing (IFA for IgG or IgM) requires appropriately timed acute and convalescent specimens: initial and confirmatory IFA testing should be performed at least two weeks apart to demonstrate a rise in antibody titer.

Collect acute specimen at presentation and a convalescent specimen ≥ 2 weeks later for IFA serology
Consider blood smear microscopy or NAAT for earlier detection while awaiting convalescent serology

Documentation Required

Rickettsial serology timing

For suspected rickettsial disease, IgG IFA serologic testing should include appropriately timed acute and convalescent specimens: initial and confirmatory IgG IFA testing should be a minimum of two weeks apart to document seroconversion or a significant titer rise. NAAT and IgM IFA are generally not reimbursed for rickettsial disease.

Obtain acute and convalescent serum specimens at least 2 weeks apart for IgG IFA testing
NAAT and IgM IFA testing for rickettsial disease are generally not reimbursed — rely on IgG convalescent testing for confirmation

Denial Risk

WNV NAAT denial risk

NAAT for West Nile virus (WNV) is reimbursable for confirming infection in immunocompromised individuals but may not be reimbursed for immunocompetent individuals. Order WNV NAAT only when the patient meets criteria (e.g., immunocompromised status); otherwise rely on serologic testing (IgM/IgG) and confirmatory PRNT as indicated.

WNV NAAT: reimbursable for immunocompromised patients when clinically indicated
WNV NAAT: not reimbursable (denial risk) for immunocompetent patients — document immunocompromised status if NAAT is ordered

Denial Risk

Asymptomatic screening denial risk

Testing for vector-borne infections during routine, asymptomatic general exams without abnormal findings may not be reimbursed. Avoid ordering surveillance or screening tests in asymptomatic individuals unless specific exposure, symptoms, or clinical findings warrant testing.

Do not order vector-borne infection tests for asymptomatic screening during general exams without abnormal findings
Document symptoms, exposure history, or clinical findings to support medical necessity if testing is ordered

Ordering Requirements and Patient Factors

Note

Confirm indications: pregnancy, travel/exposure, and immune status

Ordering indications vary by clinical context — consider pregnancy status, travel/exposure history, and immune status when selecting tests (for example, Zika NAAT windows and WNV NAAT reimbursement differ by pregnancy and immune status).

Zika NAAT: reimbursed up to 12 weeks for symptomatic pregnant individuals with relevant exposure; limited windows for non-pregnant symptomatic travelers.
WNV NAAT: reimbursed for immunocompromised individuals only; not reimbursed for immunocompetent individuals.

Definitions

inv-15: Relapsing fever definitions and testing approaches

DefinitionRelapsing fever: infection caused by Borrelia species characterized by recurrent febrile episodes; includes HTRF, LBRF, STRF/TBRF

HTRF (Hard-tick relapsing fever)Typical agents include Borrelia miyamotoi; testing approach: serologic assays for Borrelia antibodies or NAAT for B. miyamotoi

LBRF (Louse-borne relapsing fever)Typical agent: Borrelia recurrentis; testing approach: peripheral blood smear microscopy or NAAT for B. recurrentis

STRF/TBRF (Soft-tick/other tick-borne relapsing fever)Typical agents include B. hermsii, B. turicatae, and other Borrelia spp.; testing approach: dark-field microscopy, Wright/Giemsa-stained peripheral smear, NAAT for Borrelia spp., or serologic assays

Background

Arthropod vectors (mosquitoes, ticks, fleas, and mites) transmit viruses, bacteria, and protozoa that cause diseases covered by this policy, including Zika, West Nile virus, dengue, chikungunya, malaria, babesiosis, ehrlichiosis/anaplasmosis, rickettsial diseases, and relapsing fevers due to Borrelia. Diagnostic methods referenced in the policy include blood smear microscopy (including dark-field and special stains), culture, nucleic acid amplification testing (NAAT), antigen detection (e.g., NS1 for dengue), and serologic assays (IFA, ELISA, plaque reduction neutralization tests). Selection of test modality depends on the suspected pathogen, timing of specimen collection, pregnancy or immune status, and clinical scenario.

OpenPayer